Study of octreotide microspheres for neuroendocrine tumors
Part of Cancer clinical trials.
This trial looks at how well octreotide microspheres work for people with neuroendocrine tumors that cannot be removed by surgery or have spread to other parts of the body. It aims to help doctors understand the real-world benefits of this treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of tumor called a neuroendocrine tumor that cannot be removed by surgery or has spread to other parts of your body.
- If your tumor came back or grew after surgery or other local treatments, you may still qualify.
- You are scheduled to receive or are already receiving treatment with octreotide microspheres.
- You are 18 years old or older.
- You agree to participate and sign a consent form.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a treatment called PRRT, which delivers a radioactive medicine directly to tumor cells, for advanced neuroendocrine tumors. It may help those whose tumors are growing despite octreotide treatment, especially when scans show tumor uptake of specific tracers.
This trial asks adults with a neuroendocrine tumor to share their study experiences through surveys or interviews. It may help researchers understand what supports or challenges people face during care and research.
This trial looks at how useful a specific scan (68Ga-DOTA-TATE PET/CT) is for tumors that have certain “targets” (somatostatin receptors). It may help doctors better identify and guide care for neuroendocrine tumors.
This Phase 3 study tests whether a targeted radiation treatment approach (using a special “PRRT” scan-guided method) works better to control advanced neuroendocrine tumors. It’s designed for tumors that show strong targeting on a specific PET scan and that are growing despite prior treatment (with some limits).
This study uses a special PET scan called 18F-AlF-NOTA-Octreotide to get clear images of neuroendocrine tumors. It can help doctors see where the tumors are and how active they are, which may guide treatment decisions.
This trial tests a combination of two drugs, sirolimus and octreotide, for people with advanced neuroendocrine tumors in the digestive system that cannot be removed by surgery and are not making excess hormones. The goal is to see if this combination can help control the tumors.
Hear when a new Neuroendocrine Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.